Wapner on Avastin

Always interesting and engaging, Jessica Wapner has discussed the bevacizumab (Avastin) saga and a recent recommendation made to the FDA that the drug is not appropriate for the treatment of breast cancer. It is a difficult example because the drug is prohibitively expensive, will evoke a positive response in a relatively small proportion of patients, and is potentially unsafe for others.

Insurance companies are amongst the very few stakeholders that genuinely benefit from improving the health of their customers. The US is notoriously bad with their quality-to-cost ratio. Given these issues, is it such a bad thing if the insurance companies use their power as a counterweight to the pharmaceutical industry – promoting cost-effective care instead of inflating the profitability of bad drugs and over-prescribing?

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s